A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of E1K After Single Dose in Patients With Knee Osteoarthritis
Latest Information Update: 17 Jan 2024
Price :
$35 *
At a glance
- Drugs ENGEDI-1000 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Ensol Biosciences
- 10 Jan 2024 Status changed from recruiting to completed.
- 30 Jan 2023 New trial record